About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.
Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.
PMID: 35678104 Journal: PSYCHOPHYSIOLOGY Year: 2022 Reference: Psychophysiology. 2022 Jun 9:e14108. doi: 10.1111/psyp.14108. Impact factor: 4.016 Publication type: Paper in international publication Authors: Pozo-Rosich, Patricia, Soto-Faraco, Salvador, Torralba Cuello, Mireia, Marti-Marca, Angela, Vila-Ballo, Adria et al. DOI: 10.1111/psyp.14108
PMID: 35670131 Journal: HEADACHE Year: 2022 Reference: Headache. 2022 Jun;62(6):648-649. doi: 10.1111/head.14330. Epub 2022 Jun 7. Impact factor: 5.887 Publication type: Letter or abstract Authors: Pozo-Rosich, Patricia, Caronna, Edoardo et al. DOI: 10.1111/head.14330
PMID: 35639404 Journal: JOURNAL OF VISION Year: 2022 Reference: J Vis. 2022 May 3;22(6):10. doi: 10.1167/jov.22.6.10. Impact factor: 2.154 Publication type: Paper in international publication Authors: Otazu, Xavier, Cerda-Company, Xim et al. DOI: 10.1167/jov.22.6.10
PMID: 35491662 Journal: INTERVENTIONAL NEURORADIOLOGY Year: 2022 Reference: Interv Neuroradiol. 2022 May 2:15910199221095798. doi: 10.1177/15910199221095798. Impact factor: 1.61 Publication type: Paper in international publication Authors: Requena, Manuel, Pinana, Carlos, Olive-Gadea, Marta, Hernandez, David, Boned, Sandra, De Dios, Marta, Rodrigo, Marc, Rivera, Eila, Muchada, Marian, Cuevas, Jose Luis et al. DOI: 10.1177/15910199221095798
PMID: 33472427 Journal: CEPHALALGIA Year: 2021 Reference: Cephalalgia. 2021 Mar;41(3):279-293. doi: 10.1177/0333102421989247. Epub 2021 Jan 20. Impact factor: Publication type: Paper in international publication Authors: Ashina, Messoud; Diener, Hans Christoph; Durand-Zaleski, Isabelle; Kurth, Tobias; Lanteri-Minet, Michel; Lipton, Richard B; Ollendorf, Daniel A; Pozo-Rosich, Patricia; Tassorelli, Cristina; Terwindt, Gisela et al. DOI: 10.1177/0333102421989247
PMID: 32838536 Journal: CEPHALALGIA Year: 2021 Reference: Cephalalgia. 2021 Jan;41(1):45-57. doi: 10.1177/0333102420951509. Epub 2020 Aug 24. Impact factor: Publication type: Paper in international publication Authors: Alpuente, Alicia; Gallardo, Victor Jose; Marti-Marca, Angela; Pozo-Rosich, Patricia; Torres-Ferrus, Marta; Vila-Ballo, Adria et al. DOI: 10.1177/0333102420951509
PMID: 32718873 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia. 2021 Jan - Feb;36(1):61-79. doi: 10.1016/j.nrl.2020.04.022. Epub 2020 Jul 25. Impact factor: Publication type: Paper in national publication Authors: Belvis, R; Garcia-March, G; Gonzalez-Oria, C; Irimia, P; Lainez, J M; Latorre, G; Paz, J; Pozo-Rosich, P; Rodriguez, R; Santos-Lasasosa, S et al. DOI: 10.1016/j.nrl.2020.04.022
PMID: 33223077 Journal: NEUROLOGIC CLINICS Year: 2021 Reference: Neurol Clin. 2021 Feb;39(1):1-19. doi: 10.1016/j.ncl.2020.09.001. Epub 2020 Nov 7. Impact factor: Publication type: Review in international publication Authors: Caronna, Edoardo; Starling, Amaal J et al. DOI: 10.1016/j.ncl.2020.09.001
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.
